SecBot SecBot

DYN drug pipeline

Dyne Therapeutics, Inc. · 3 rated drugs
$17.16
+0.9% 1-day · Nov 13
Next catalyst
Jan 21, 2027
z-rostudirsen PDUFA date · in 66 days
Typical move on FDA news
±0.7%
1-day, median of 4 events
IV rank
No data
No current options data
Rated drugs
3
1 bullish · 1 mixed · 1 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

2 dated
  1. Jan 21, 202766d
    z-rostudirsen
    PDUFA date · Duchenne muscular dystrophy amenable to exon 51 skipping
  2. Q3 2027
    z-basivarsen
    BLA filing · myotonic dystrophy type 1 (DM1)

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseFiled (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing
Time to marketPotential U.S. launch in Q1 2027 if approved — BLA is under FDA Priority Review with a PDUFA target action date of January 21, 2027 (accelerated approval based on dystrophin as a surrogate endpoint).

z-rostudirsen Updated Aug 20

66days
Next catalyst
PDUFA date · Jan 21, 2027 · Duchenne muscular dystrophy amenable to exon 51 skipping
What to watch

The January 21, 2027 PDUFA is the binary to trade: approval odds look favorable (Priority Review, positive Phase 1/2 data, dystrophin surrogate endpoint), but an Accelerated Approval tied to a surrogate plus an unfinished confirmatory trial (FORZETTO) leaves room for a surprise CRL. Watch for an FDA Advisory Committee date in Q4 2026, the Q3 2026 earnings call for any label/launch commentary, and note the heavy 10b5-1 insider selling and ~57% weighted short-volume ratio as overhangs into the decision.

Bull case
  • FDA accepted the z-rostudirsen BLA with Priority Review and set a PDUFA target action date of January 21, 2027 (8-K filed July 20, 2026; Q2 2026 earnings release), putting a potential first U.S. launch in Q1 2027 within reach.
  • Phase 1/2 DELIVER topline showed statistically significant dystrophin expression and functional improvement, including a statistically significant gain on the primary functional endpoint (RFF velocity) at 6 months, and 24-month data showed heart/lung function improvement vs. natural-history decline (press releases March 2026, 2026 MDA Conference).
  • Wall Street is broadly positive: consensus is strong_buy (19 Buy/Strong Buy vs. 2 Hold, 0 Sell) with a mean price target of $39.40 and median $40 vs. a ~$26.78 last price (~49% implied upside).
Bear case
  • Approval is an Accelerated Approval based on dystrophin as a surrogate endpoint; the confirmatory FORZETTO trial is still enrolling and its success, years away, determines whether approval becomes traditional, leaving a real post-approval overhang.
  • Shareholder dilution: July 2026 upsized offering of 18.3M shares at $20.50 (~$375M gross) was assessed as diluting existing holders by roughly 9-11% including the underwriter option; the Q2 2026 release also cites a $431M offering and a $400M debt facility.
  • Heavy insider selling into strength: director Jason P. Rhodes (Atlas Venture) sold ~1.36M + ~478K + ~322K shares (~$54M combined reported value) on Aug 14, 2026 under a 10b5-1 plan adopted July 13, 2026, with additional insider sales by officers in July-August 2026.
◆ mixed
Impact
PhasePhase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled
Time to marketPotential U.S. launch as soon as H1 2028 if Q1 2027 ACHIEVE topline data support a Q3 2027 Accelerated-Approval BLA (company guidance); otherwise later or never.

z-basivarsen Updated Aug 1

Q3 2027
Next catalyst
BLA filing · Q3 2027 · myotonic dystrophy type 1 (DM1)
What to watch

The single binary to watch for THIS drug is the ACHIEVE topline readout in Q1 2027, a strong result supports a Q3 2027 accelerated-approval BLA and a potential H1 2028 U.S. launch; a weak result would hit a ~$3.9B market cap hard. Note the stock may also trade on Dyne's OTHER drug (z-rostudirsen DMD PDUFA Jan 21, 2027) before the DM1 readout, and watch for any 2026 conference data previews.

Bull case
  • Registrational derisking: the ACHIEVE registrational expansion cohort (71 participants) is fully enrolled, with topline data guided for Q1 2027, a key milestone per Dyne's June 3, 2026 release and 8-K, followed by a potential BLA for U.S. Accelerated Approval in Q3 2027 and launch in H1 2028.
  • A confirmatory Phase 3 (HARMONIA) was already initiated in March 2026, giving an accelerated-approval path a running confirmatory study.
  • Well-funded to the catalyst: after the upsized ~$375M offering (18.3M shares at $20.50) and a $400M Hercules debt facility, management guided cash runway into Q2 2028 (Q2 2026 earnings), covering the readout and BLA.
Bear case
  • True binary risk: Q1 2027 ACHIEVE topline is a make-or-break readout on a first-in-class mechanism in a disease with no approved disease-modifying therapy, and the stock already carries a ~$3.9B market cap.
  • Competition is ahead: Avidity Biosciences' del-desiran (AOC 1001) Phase 3 HARBOR DM1 trial had an estimated primary completion of Aug 2026, before Dyne's Q1 2027 readout; PepGen and Entrada also have DM1 programs (PepGen's under an FDA partial clinical hold).
  • Dilution: Dyne priced an upsized 18.3M-share offering at $20.50 in July 2026, assessed as ~9-11% dilution, and a commercial build-out will likely need more capital.
● neutral
Impact
PhaseNot stated
Time to marketunknown — no clinical trial, FDA, or company disclosure record for DYNE-302 could be verified this session; absence from ingested ClinicalTrials.gov/FDA data suggests it is at most an early/preclinical-stage program, but this cannot be confirmed.

DYNE-302 Updated Aug 1

What to watch

Near-term DYN moves will be driven by z-rostudirsen's PDUFA (Jan 21, 2027) and z-basivarsen's Q1 2027 topline, not by this program.

Bull case
  • Developer is a confirmed, well-covered Nasdaq name: Dyne Therapeutics (DYN) has 18 of 21 analysts at Buy/Strong Buy with a mean price target of $39.53 versus a ~$25.18 price (implied upside ~58.9%) per SecBot's 2026-07-31 analyst snapshot.
  • Dyne has deep cash: it raised $375.15M gross in a July 2026 upsized offering and expanded its credit facility to $400M, with runway into Q2 2028 per its Q2 2026 release, so an early-stage program like DYNE-302 would be well funded.
  • If DYNE-302 is a next platform program (by naming convention after DYNE-101/DYNE-251), it would ride Dyne's established muscle-targeted antisense delivery platform, which has already produced positive data in DMD (DELIVER trial) and a completed-registrational-cohort DM1 trial.
Bear case
  • No scheduled binary catalyst: the next hard dates for DYN (z-rostudirsen PDUFA 2027-01-21; z-basivarsen topline Q1 2027) belong to other drugs; DYNE-302 has no dated catalyst in the next ~12 months.
  • If it is early-stage/preclinical, it carries typical development risk, no clinical data exists to evaluate efficacy or safety, and it contributes nothing to near-term value.
  • Shareholder dilution: Dyne sold 18.3M shares at $20.50 in July 2026 (about 9-11% dilution per press analysis) and insiders have been selling (e.g., director Kersten Dirk sold ~$6.5M of stock on 2026-07-27 under a 10b5-1 plan).

Past FDA events & how the stock moved

4 events
DateDrugEvent1 day5 days
Jul 29, 2026z-rostudirsenBLA filed−0.7%+1.0%
Jul 29, 2026DYNE-302Approval−0.7%+1.0%
Jul 29, 2026z-rostudirsenPriority review−0.7%+1.0%
Jul 1, 2026z-rostudirsenBLA filed+3.9%+9.3%